Drug intelligence / Profile preview

yimitasvir

Development stage: Phase 3
Lead developer: Changjiang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Yimitasvir is a novel, orally active small molecule inhibitor of the hepatitis C virus (HCV) nonstructural protein 5A (NS5A). It is primarily developed for the treatment of chronic HCV infection, particularly genotype 1. Yimitasvir acts by specifically inhibiting NS5A, a viral protein essential for HCV RNA replication and assembly. The drug has been studied in combination with sofosbuvir and has reached phase III clinical trials in China. It was originally developed by HEC Pharm and Dongguan HEC TaiGen Biopharmaceuticals[3][4][5][6]. The compound is also known as yimitasvir phosphate when formulated as its phosphate salt.

Brand names: 东卫恩
Other names: yimitasvir phosphateEmitasvir

Targets

NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))

Beyond the preview

Go deeper on yimitasvir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on yimitasvir.

Explore the full profile